Abstract
Objectives: To investigate the association between serum uric acid levels, cardiovascular risk, and arterial stiffness in She ethnic minority in South China’s Fujian Province. Methods: 5109 participants aged 20–79 yr were enrolled in analysis. Tpeak-Tend interval (Tp-e), QT interval, and height of the R wave in lead aVL (aVLR) were measured on 12-lead electrocardiogram (ECG), and Minnesota code-indicated major abnormal ECG MA-ECG was used as a risk indicator of cardiovascular disease. Arterial stiffness was assessed by brachial-ankle pulse wave velocity (baPWV). Results: Longer Tp-e interval, greater Tp-e/QT ratio, and higher aVLR were observed in the highest quartile of uric acid level. The incidence of MA-ECG was gradually increased from lowest to highest quartile of serum uric acid in males (p for trend <0.01). After adjusting traditional cardiovascular risk factors, multivariate analysis revealed that the fourth quartile of serum uric acid level was independently associated with MA-ECG in males [odds ratios (OR) (95% confidence interval): 2.129 (1.376-3.295)] but not in females. Serum uric acid was also associated with abnormal baPWV, when adjusted for atherogenic confounders. Compared with the lowest serum uric acid quartile, the OR (95% confidence interval) of the second, third, and fourth quartile were 1.920 (1.246-2.957), 1.650 (1.064-2.558), and 2.501 (1.600-3.908) in males. Conclusion: Among China’s She ethnic minority, uric acid level was independently related to arterial stiffness assessed by baPWV in both genders. The evaluation of uric acid level was related to higher cardiovascular risk in males but not in females.
Similar content being viewed by others
References
Feig DI, Kang DH, Johnson RJ. Uric acid and cardiovascular risk. N Engl J Med 2008, 359: 1811–21.
Moriarity JT, Folsom AR, Iribarren C, Nieto FJ, Rosamond WD. Serum uric acid and risk of coronary heart disease: Atherosclerosis Risk in Communities (ARIC) Study. Ann Epidemiol 2000, 10: 136–43.
Wheeler JG, Juzwishin KD, Eiriksdottir G, Gudnason V, Danesh J. Serum uric acid and coronary heart disease in 9,458 incident cases and 155,084 controls: prospective study and meta-analysis. PLoS Med 2005, 2: e76.
Hunsicker LG, Adler S, Caggiula A, et al. Predictors of the progression of renal disease in the Modification of Diet in Renal Disease Study. Kidney Int 1997, 51: 1908–19.
Cannon PJ, Stason WB, Demartini FE, Sommers SC, Laragh JH. Hyperuricemia in primary and renal hypertension. N Engl J Med 1966, 275: 457–64.
Ford ES, Li C, Cook S, Choi HK. Serum concentrations of uric acid and the metabolic syndrome among US children and adolescents. Circulation 2007, 115: 2526–32.
Tuttle KR, Short RA, Johnson RJ. Sex differences in uric acid and risk factors for coronary artery disease. Am J Cardiol 2001, 87: 1411–4.
Weir CJ, Muir SW, Walters MR, Lees KR. Serum urate as an independent predictor of poor outcome and future vascular events after acute stroke. Stroke 2003, 34: 1951–6.
Talaat KM, el-Sheikh AR. The effect of mild hyperuricemia on urinary transforming growth factor beta and the progression of chronic kidney disease. Am J Nephrol 2007, 27: 435–40.
Chen JH, Chuang SY, Chen HJ, Yeh WT, Pan WH. Serum uric acid level as an independent risk factor for all-cause, cardiovascular, and ischemic stroke mortality: a Chinese cohort study. Arthritis Rheum 2009, 61: 225–32.
Choi CU, Park EB, Suh SY, et al. Impact of aortic stiffness on cardiovascular disease in patients with chest pain: assessment with direct intra-arterial measurement. Am J Hypertens 2007, 20: 1163–9.
Yamashina A, Tomiyama H, Arai T, et al. Brachial-ankle pulse wave velocity as a marker of atherosclerotic vascular damage and cardiovascular risk. Hypertens Res 2003, 26: 615–22.
Nagano M, Nakamura M, Sato K, Tanaka F, Segawa T, Hiramori K. Association between serum C-reactive protein levels and pulse wave velocity: a population-based cross-sectional study in a general population. Atherosclerosis 2005, 180: 189–95.
Yamashina A, Tomiyama H, Takeda K, et al. Validity, reproducibility, and clinical significance of noninvasive brachial-ankle pulse wave velocity measurement. Hypertens Res 2002, 25: 359–64.
Tomiyama H, Yamashina A, Arai T, et al. Influences of age and gender on results of noninvasive brachial-ankle pulse wave velocity measurement-a survey of 12517 subjects. Atherosclerosis 2003, 166: 303–9.
Kuo CF, Yu KH, Luo SF, et al. Role of uric acid in the link between arterial stiffness and cardiac hypertrophy: a cross-sectional study. Rheumatology (Oxford) 2010, 49: 1189–96.
Ishizaka N, Ishizaka Y, Toda E, Hashimoto H, Nagai R, Yamakado M. Higher serum uric acid is associated with increased arterial stiffness in Japanese individuals. Atherosclerosis 2007, 192: 131–7.
Horibe H, Kasagi F, Kagaya M, Matsutani Y, Okayama A, Ueshima H; NIPPON TATA80 Research Group; Working Group of Electrocardiographic Coding for the National Survey of Circulatory Disorders, 1980. A nineteen-year cohort study on the relationship of electrocardiographic findings to all cause mortality among subjects in the national survey on circulatory disorders, NIPPON DA-TA80. J Epidemiol 2005, 15: 125–34.
De Bacquer D, De Backer G, Kornitzer M, Blackburn H. Prognostic value of ECG findings for total, cardiovascular disease, and coronary heart disease death in men and women. Heart 1998, 80: 570–7.
Verdecchia P, Angeli F, Cavallini C, et al. The voltage of R wave in lead aVL improves risk stratification in hypertensive patients without ECG left ventricular hypertrophy. J Hypertens 2009, 27: 1697–704.
Blackburn H, Keys A, Simonson E, Rautaharju P, Punsar S. The electrocardiogram in population studies. A classification system. Circulation 1960, 21: 1160–75.
Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972, 18: 499–502.
Fang J, Alderman MH. Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow-up study, 1971–1992. National Health and Nutrition Examination Survey. JAMA 2000, 283: 2404–10.
Tan CE, Ma S, Wai D, Chew SK, Tai ES. Can we apply the National Cholesterol Education Program Adult Treatment Panel definition of the metabolic syndrome to Asians? Diabetes Care 2004, 27: 1182–6.
Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003, 289: 2560–72.
Pooling Project Research Group. Relationship of blood pressure, serum cholesterol, smoking habit, relative weight and ECG abnormalities to incidence of major coronary events: final report of the pooling project. The pooling project research group. J Chronic Dis 1978, 31: 201–306.
Erdogan D, Gullu H, Caliskan M, et al. Relationship of serum uric acid to measures of endothelial function and atherosclerosis in healthy adults. Int J Clin Pract 2005, 59: 1276–82.
Gupta P, Patel C, Patel H, et al. T(p-e)/QT ratio as an index of arrhythmogenesis. J Electrocardiol 2008, 41: 567–74.
Iwashima Y, Horio T, Kamide K, Rakugi H, Ogihara T, Kawano Y. Uric acid, left ventricular mass index, and risk of cardiovascular disease in essential hypertension. Hypertension 2006, 47: 195–202.
Kurata A, Shigematsu Y, Higaki J. Sex-related differences in relations of uric acid to left ventricular hypertrophy and remodeling in Japanese hypertensive patients. Hypertens Res 2005, 28: 133–9.
Matsumura K, Ohtsubo T, Oniki H, Fujii K, Iida M. Gender-related association of serum uric acid and left ventricular hypertrophy in hypertension. Circ J 2006, 70: 885–8.
Mitsuhashi H, Yatsuya H, Matsushita K, et al. Uric acid and left ventricular hypertrophy in Japanese men. Circ J 2009, 73: 667–72.
Verdecchia P, Schillaci G, Reboldi G, Santeusanio F, Porcellati C, Brunetti P. Relation between serum uric acid and risk of cardiovascular disease in essential hypertension. The PIUMA study. Hypertension 2000, 36: 1072–8.
Anker SD, Doehner W, Rauchhaus M, et al. Uric acid and survival in chronic heart failure: validation and application in metabolic, functional, and hemodynamic staging. Circulation 2003, 107: 1991–7.
Culleton BF, Larson MG, Kannel WB, Levy D. Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study. Ann Intern Med 1999, 131: 7–13.
Freedman DS, Williamson DF, Gunter EW, Byers T. Relation of serum uric acid to mortality and ischemic heart disease. The NHANES I Epidemiologic Follow-up Study. Am J Epidemiol 1995, 141: 637–44.
Sumino H, Ichikawa S, Kanda T, Nakamura T, Sakamaki T. Reduction of serum uric acid by hormone replacement therapy in postmenopausal women with hyperuricaemia. Lancet 1999, 354: 650.
Liu PW, Chang TY, Chen JD. Serum uric acid and metabolic syndrome in Taiwanese adults. Metabolism 2010, 59: 802–7.
Sánchez-Lozada LG, Tapia E, Bautista-García P, et al. Effects of febuxostat on metabolic and renal alterations in rats with fructose-induced metabolic syndrome. Am J Physiol Renal Physiol 2008, 294: F710–8.
Nakagawa T, Hu H, Zharikov S, et al. A causal role for uric acid in fructose-induced metabolic syndrome. Am J Physiol Renal Physiol 2006, 290: F625–31.
Hung CS, Lin JW, Hsu CN, et al. Using brachial-ankle pulse wave velocity to associate arterial stiffness with cardiovascular risks. Nutr Metab Cardiovasc Dis 2009, 19: 241–6.
Ishizaka N, Ishizaka Y, Toda E, Nagai R, Yamakado M. Association between serum uric acid, metabolic syndrome, and carotid atherosclerosis in Japanese individuals. Arterioscler Thromb Vasc Biol 2005, 25: 1038–44.
Arruda CG AJ, Bortolotto LA, Alecrin IN, Ramires JA. Effects of estradiol alone and combined with norethisterone acetate on pulse-wave velocity in hypertensive postmenopausal women. Gynecol Endocrinol 2006, 22: 557–63.
Khosla UM, Zharikov S, Finch JL, et al. Hyperuricemia induces endothelial dysfunction. Kidney Int 2005, 67: 1739–42.
Kato M, Hisatome I, Tomikura Y, et al. Status of endothelial dependent vasodilation in patients with hyperuricemia. Am J Cardiol 2005, 96: 1576–8.
Johnson RJ, Kang DH, Feig D, et al. Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? Hypertension 2003, 41: 1183–90.
Kanellis J, Watanabe S, Li JH, et al. Uric acid stimulates monocyte chemoattractant protein-1 production in vascular smooth muscle cells via mitogen-activated protein kinase and cyclooxygenase-2. Hypertension 2003, 41: 1287–93.
Rao GN, Corson MA, Berk BC. Uric acid stimulates vascular smooth muscle cell proliferation by increasing platelet-derived growth factor A-chain expression. J Biol Chem 1991, 266: 8604–8.
Messerli F, Frohlich E, Dreslinski G, Suarez D, Aristimuno G. Serum uric acid in essential hypertension: an indicator of renal vascular involvement.. Ann Intern Med 1980, 93: 817–21.
Iwashima Y, Horio T, Kuroda S, Takishita S, Kawano Y. Influence of plasma aldosterone on left ventricular geometry and diastolic function in treated essential hypertension. Hypertens Res 2002, 25: 49–56.
Zeng QY, Chen R, Darmawan J, et al. Rheumatic diseases in China. Arthritis Res Ther 2008, 10: R17.
Chang HY, Pan WH, Yeh WT, Tsai KS. Hyperuricemia and gout in Taiwan: results from the Nutritional and Health Survey in Taiwan (1993–96). J Rheumatol 2001, 28: 1640–6.
Conen D, Wietlisbach V, Bovet P, et al. Prevalence of hyperuricemia and relation of serum uric acid with cardiovascular risk factors in a developing country. BMC Public Health 2004, 4: 9.
Author information
Authors and Affiliations
Corresponding author
Additional information
The first four authors contributed to the study equally.
Rights and permissions
About this article
Cite this article
Lin, Y., Lai, X., Chen, G. et al. Association among serum uric acid, cardiovascular risk, and arterial stiffness: A cross-sectional study in She ethnic minority group of Fujian Province in China. J Endocrinol Invest 35, 290–297 (2012). https://doi.org/10.3275/7765
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.3275/7765